PL3120852T3 - Środek zapobiegawczy i/lub terapeutyczny przeciwko chorobom immunologicznym - Google Patents

Środek zapobiegawczy i/lub terapeutyczny przeciwko chorobom immunologicznym

Info

Publication number
PL3120852T3
PL3120852T3 PL16743556T PL16743556T PL3120852T3 PL 3120852 T3 PL3120852 T3 PL 3120852T3 PL 16743556 T PL16743556 T PL 16743556T PL 16743556 T PL16743556 T PL 16743556T PL 3120852 T3 PL3120852 T3 PL 3120852T3
Authority
PL
Poland
Prior art keywords
preventive
therapeutic agent
immune diseases
immune
diseases
Prior art date
Application number
PL16743556T
Other languages
English (en)
Inventor
Fumihito HOSOI
Yoshinori NAKACHI
Daisuke Kajiwara
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3120852T3 publication Critical patent/PL3120852T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL16743556T 2015-01-30 2016-01-29 Środek zapobiegawczy i/lub terapeutyczny przeciwko chorobom immunologicznym PL3120852T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015017386 2015-01-30
PCT/JP2016/052732 WO2016121953A1 (ja) 2015-01-30 2016-01-29 免疫疾患の予防及び/又は治療剤
EP16743556.9A EP3120852B1 (en) 2015-01-30 2016-01-29 Preventive and/or therapeutic agent for immune diseases

Publications (1)

Publication Number Publication Date
PL3120852T3 true PL3120852T3 (pl) 2019-09-30

Family

ID=56543555

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16743556T PL3120852T3 (pl) 2015-01-30 2016-01-29 Środek zapobiegawczy i/lub terapeutyczny przeciwko chorobom immunologicznym

Country Status (21)

Country Link
US (1) US9782412B2 (pl)
EP (1) EP3120852B1 (pl)
JP (1) JP6093485B2 (pl)
KR (1) KR101858421B1 (pl)
CN (2) CN107206001B (pl)
AU (1) AU2016213030B2 (pl)
BR (1) BR112017016278B1 (pl)
CA (1) CA2975372C (pl)
DK (1) DK3120852T3 (pl)
ES (1) ES2734364T3 (pl)
HU (1) HUE045532T2 (pl)
MX (1) MX381234B (pl)
MY (1) MY197518A (pl)
PH (1) PH12017501336B1 (pl)
PL (1) PL3120852T3 (pl)
PT (1) PT3120852T (pl)
RU (1) RU2705154C2 (pl)
SG (1) SG11201704430SA (pl)
TR (1) TR201910158T4 (pl)
TW (1) TWI638817B (pl)
WO (1) WO2016121953A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101852738B1 (ko) * 2015-01-30 2018-04-27 다이호야쿠힌고교 가부시키가이샤 축합 피리미딘 화합물의 신규한 염 및 그 결정
US11236070B2 (en) * 2019-05-16 2022-02-01 Novartis Ag Chemical process
US20230064254A1 (en) * 2019-12-19 2023-03-02 Taiho Pharmaceutical Co., Ltd. Therapeutic agent containing fused pyrimidine compound as active ingredient
CN112209894B (zh) * 2020-10-23 2023-06-06 贵州医科大学 5-芳基取代2-氨基苯并恶唑类衍生物、制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2073810B1 (en) * 2006-09-13 2011-08-31 Takeda Pharmaceutical Company Limited Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
CA2668286C (en) * 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
WO2009057733A1 (ja) * 2007-10-31 2009-05-07 Santen Pharmaceutical Co., Ltd. 血管新生阻害活性を有する新規インドール誘導体
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
DK2657233T3 (da) 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf
JP2015526520A (ja) * 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Itk阻害剤としてのベンズイミダゾール誘導体
KR101828187B1 (ko) 2013-08-12 2018-02-09 다이호야쿠힌고교 가부시키가이샤 신규 축합 피리미딘 화합물 또는 그 염

Also Published As

Publication number Publication date
CN113768935B (zh) 2024-10-01
ES2734364T3 (es) 2019-12-05
WO2016121953A1 (ja) 2016-08-04
RU2017127126A (ru) 2019-03-01
AU2016213030B2 (en) 2019-01-31
PH12017501336B1 (en) 2023-10-20
HUE045532T2 (hu) 2020-01-28
BR112017016278A2 (pt) 2018-03-27
MY197518A (en) 2023-06-19
CA2975372A1 (en) 2016-08-04
MX381234B (es) 2025-03-12
CA2975372C (en) 2020-01-14
JP6093485B2 (ja) 2017-03-08
SG11201704430SA (en) 2017-08-30
TWI638817B (zh) 2018-10-21
AU2016213030A1 (en) 2017-06-22
US20170042900A1 (en) 2017-02-16
CN113768935A (zh) 2021-12-10
PH12017501336A1 (en) 2017-12-11
PT3120852T (pt) 2019-07-16
RU2705154C2 (ru) 2019-11-05
BR112017016278B1 (pt) 2022-05-10
KR20170083640A (ko) 2017-07-18
CN107206001B (zh) 2021-09-28
TR201910158T4 (tr) 2019-07-22
MX2017009863A (es) 2017-11-15
EP3120852A4 (en) 2017-05-24
CN107206001A (zh) 2017-09-26
KR101858421B1 (ko) 2018-05-15
TW201632526A (zh) 2016-09-16
EP3120852B1 (en) 2019-05-01
RU2017127126A3 (pl) 2019-03-01
EP3120852A1 (en) 2017-01-25
DK3120852T3 (da) 2019-07-29
US9782412B2 (en) 2017-10-10
JPWO2016121953A1 (ja) 2017-04-27

Similar Documents

Publication Publication Date Title
SG11201801024XA (en) Therapeutic or preventive compositions for il-8-related diseases
IL250990A0 (en) Materials for human care
PL3120852T3 (pl) Środek zapobiegawczy i/lub terapeutyczny przeciwko chorobom immunologicznym
GB201503139D0 (en) Diagnostic and therapeutic target
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
GB201519644D0 (en) Therapy and pharmaceutical composition
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
GB201500555D0 (en) Method and device for the treatment of diseases
GB201521260D0 (en) Therapeutic and diagnostic target
GB201521259D0 (en) Therapeutic and diagnostic target
GB201521264D0 (en) Therapeutic and diagnostic target
GB201521262D0 (en) Therapeutic and diagnostic target
GB201518310D0 (en) Therapeutic and diagnostic target
GB201518309D0 (en) Therapeutic and diagnostic target
GB201518307D0 (en) Therapeutic and diagnostic target
GB201518306D0 (en) Therapeutic and diagnostic target
GB201518188D0 (en) Therapeutic and diagnostic target
GB201518187D0 (en) Therapeutic and diagnostic target
GB201513119D0 (en) Therapeutic and diagnostic target
GB201513114D0 (en) Therapeutic and diagnostic target
GB201513070D0 (en) Therapeutic and diagnostic target
GB201513004D0 (en) Therapeutic and diagnostic target
GB201516109D0 (en) Therapeutic agent
GB201504863D0 (en) Therapeutic and diagnostic target
GB201504865D0 (en) Therapeutic and diagnostic target